Cargando…

Biomarkers in Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD) is a progressive neurodegenerative disease. AD is the main cause of dementia worldwide and aging is the main risk factor for developing the illness. AD classical diagnostic criteria rely on clinical data. However, the development of a biological definition of AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janeiro, Manuel H., Ardanaz, Carlos G., Sola-Sevilla, Noemí, Dong, Jinya, Cortés-Erice, María, Solas, Maite, Puerta, Elena, Ramírez, María J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197496/ https://www.ncbi.nlm.nih.gov/pubmed/37359199 http://dx.doi.org/10.1515/almed-2020-0090

Ejemplares similares

Biomarcadores en la enfermedad de Alzheimer
por: Janeiro, Manuel H., et al.
Publicado: (2021)

Brain Metabolic Alterations in Alzheimer’s Disease
por: Ardanaz, Carlos G., et al.
Publicado: (2022)

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target
por: Janeiro, Manuel H., et al.
Publicado: (2018)

SIRT2 as a potential new therapeutic target for Alzheimer’s disease
por: Sola-Sevilla, Noemi, et al.
Publicado: (2023)

Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
por: Ezkurdia, Amaia, et al.
Publicado: (2023)

The Cognitive Improvement and Alleviation of Brain Hypermetabolism Caused by FFAR3 Ablation in Tg2576 Mice Is Persistent under Diet-Induced Obesity
por: Solas, Maite, et al.
Publicado: (2022)

SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease
por: Sola-Sevilla, Noemi, et al.
Publicado: (2023)

c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease
por: Yarza, Ramon, et al.
Publicado: (2016)

JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology
por: Solas, Maite, et al.
Publicado: (2023)

p27, The Cell Cycle and Alzheimer´s Disease
por: García-Osta, Ana, et al.
Publicado: (2022)

JNK3 Overexpression in the Entorhinal Cortex Impacts on the Hippocampus and Induces Cognitive Deficiencies and Tau Misfolding
por: Ardanaz, Carlos G., et al.
Publicado: (2023)

Understanding the Potential Role of Sirtuin 2 on Aging: Consequences of SIRT2.3 Overexpression in Senescence
por: Sola-Sevilla, Noemi, et al.
Publicado: (2021)

Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets
por: López, Víctor, et al.
Publicado: (2017)

Expression of Endothelial NOX5 Alters the Integrity of the Blood-Brain Barrier and Causes Loss of Memory in Aging Mice
por: Cortés, Adriana, et al.
Publicado: (2021)

Comparison of Two Analytical Platforms for CSF Biomarkers of Alzheimer's Disease
por: Monge-Argilés, Jose Antonio, et al.
Publicado: (2014)

Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?
por: Mossello, Enrico, et al.
Publicado: (2010)

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease
por: Monge-García, Victoria, et al.
Publicado: (2021)

Nanomaterials towards Biosensing of Alzheimer’s Disease Biomarkers
por: Carneiro, Pedro, et al.
Publicado: (2019)

Biomarkers in Alzheimer’s Disease
por: Riverol, Mario, et al.
Publicado: (2011)

Network-Based Biomarkers in Alzheimer’s Disease: Review and Future Directions
por: Gomez-Ramirez, Jaime, et al.
Publicado: (2014)

Editorial: New insights into the role of neuroinflammation and glial cells in the development of neurological disorders
por: Pérez-González, Marta, et al.
Publicado: (2023)

Biomarkers Assessing Endothelial Dysfunction in Alzheimer’s Disease
por: Custodia, Antía, et al.
Publicado: (2023)

Calmodulin levels in blood cells as a potential biomarker of Alzheimer’s disease
por: Esteras, Noemí, et al.
Publicado: (2013)

PLD3 epigenetic changes in the hippocampus of Alzheimer’s disease
por: Blanco-Luquin, Idoia, et al.
Publicado: (2018)

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
por: Hansson, Oskar, et al.
Publicado: (2022)

Mitochondrial Haplotypes Associated with Biomarkers for Alzheimer’s Disease
por: Ridge, Perry G., et al.
Publicado: (2013)

Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer’s disease
por: Maioli, Silvia, et al.
Publicado: (2015)

Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease
por: Carapelle, Elena, et al.
Publicado: (2020)

The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer’s Disease: A Review Study
por: López-Cuenca, Inés, et al.
Publicado: (2021)

The Eye As a Biomarker for Alzheimer's Disease
por: Lim, Jeremiah K. H., et al.
Publicado: (2016)

Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease
por: Arechederra, María, et al.
Publicado: (2021)

An overview of biomarkers in Alzheimer’s disease
por: Wattamwar, Pandurang R, et al.
Publicado: (2010)

An atlas on biomarkers for Alzheimer's disease
por: Martínez-Rivera, Marta
Publicado: (2013)

Blood biomarkers for Alzheimer’s disease
por: Lovestone, Simon
Publicado: (2014)

Biomarkers for Alzheimer’s Disease Diagnosis
por: Mantzavinos, Vasileios, et al.
Publicado: (2017)

Neuroimaging Biomarkers for Alzheimer’s Disease
por: Márquez, Freddie, et al.
Publicado: (2019)

Alzheimer's disease: Newer biomarkers
por: Dangi, Ankit, et al.
Publicado: (2021)

Tear Biomarkers and Alzheimer’s Disease
por: Kaštelan, Snježana, et al.
Publicado: (2023)

Blood Biomarkers in Alzheimer’s Disease
por: Mandal, Pravat K., et al.
Publicado: (2023)

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ef1ok6arg5bbptqd6sq05e1ppr